Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Division of Gastroenterology, Interventional Endoscopy Program, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts, USA.
Gastrointest Endosc. 2020 Jul;92(1):91-96. doi: 10.1016/j.gie.2020.02.029. Epub 2020 Feb 26.
Roux-en-Y gastric bypass (RYGB) is refractory to lifestyle and pharmacotherapy measures, requiring reversal of the patient's bariatric surgery. Reversal can lead to weight regain and recrudescence of their comorbidities. Our aim was to report a multicenter experience on the endoscopic management of refractory dumping syndrome with endoscopic transoral outlet reduction (TORe).
A multicenter international series of consecutive patients who underwent TORe with a full-thickness endoscopic suturing device was analyzed for technical success, improvement in Sigstad scores, and weight trajectories after the procedure. Failure was defined as needing an enteral feeding tube, surgical reversal, or repeat TORe.
One hundred fifteen patients across 2 large academic centers in Germany and the United States underwent TORe for dumping syndrome. Patient age was mean 8.9 ± 1.1 years from their initial RYGB with an average percent total body weight loss of 31% ± 10.6% at the time of endoscopy. Three months postprocedure, the Sigstad score improved from a mean of 17 ± 6.1 to 2.6 ± 1.9 (paired t test P = .0001) with only 2% of patients (n = 2) experiencing weight gain. Mean weight loss and percentage of total body weight loss 3 months post-TORe were 9.47 ± 3.6 kg and 9.47% ± 2.5%, respectively. Six patients (5%) failed initial endoscopic therapy, with 50% (n = 3) successfully treated with a repeat TORe. Three patients underwent surgical reversal, indicating an overall 97% endoscopic success rate.
TORe as an adjunct to lifestyle and pharmacologic therapy for refractory dumping syndrome is safe and effective at improving dumping syndrome and reducing rates of surgical revision.
Roux-en-Y 胃旁路术(RYGB)对生活方式和药物治疗措施有抗药性,需要对患者的减肥手术进行逆转。逆转可能导致体重反弹和合并症复发。我们的目的是报告一项关于内镜经口输出减少术(TORe)治疗难治性倾倒综合征的多中心经验。
对在德国和美国的 2 个大型学术中心接受 TORe 治疗的难治性倾倒综合征患者进行了一项多中心国际系列连续病例分析,评估技术成功率、Sigstad 评分改善情况以及手术后的体重轨迹。失败定义为需要肠内喂养管、手术逆转或重复 TORe。
115 例患者在德国和美国的 2 个大型学术中心接受了 TORe 治疗倾倒综合征。患者年龄为初次 RYGB 后平均 8.9 ± 1.1 岁,内镜检查时平均体重量损失百分比为 31% ± 10.6%。术后 3 个月,Sigstad 评分从平均 17 ± 6.1 改善至 2.6 ± 1.9(配对 t 检验 P =.0001),仅 2%的患者(n=2)出现体重增加。TORe 后 3 个月平均体重减轻和体重量损失百分比分别为 9.47 ± 3.6 公斤和 9.47% ± 2.5%。6 例患者(5%)初次内镜治疗失败,其中 50%(n=3)经重复 TORe 成功治疗。3 例患者接受了手术逆转,表明内镜治疗的总体成功率为 97%。
TORe 作为生活方式和药物治疗难治性倾倒综合征的辅助手段,在改善倾倒综合征和降低手术修正率方面是安全有效的。